Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NASDAQ:ADTX NASDAQ:ATNF NASDAQ:COCP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$6.80-3.3%$4.90$3.80▼$41.00$10.78M-1.291.67 million shs70,387 shsADTXAditxt$0.33-22.7%$0.90$0.32▼$297.50$1.62M1.482.27 million shs2.44 million shsATNF180 Life Sciences$1.68+0.6%$3.38$0.66▼$17.75$10.15M0.3822.03 million shs5.10 million shsCOCPCocrystal Pharma$1.07$1.38$1.02▼$3.26$10.99M2.25303,719 shs105,747 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals0.00%-9.09%+56.68%-24.44%-83.41%ADTXAditxt0.00%-45.76%-67.71%-71.89%-99.88%ATNF180 Life Sciences+0.60%-15.15%-26.64%-10.64%-74.03%COCPCocrystal Pharma0.00%-6.96%-15.75%-34.76%-51.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$6.80-3.3%$4.90$3.80▼$41.00$10.78M-1.291.67 million shs70,387 shsADTXAditxt$0.33-22.7%$0.90$0.32▼$297.50$1.62M1.482.27 million shs2.44 million shsATNF180 Life Sciences$1.68+0.6%$3.38$0.66▼$17.75$10.15M0.3822.03 million shs5.10 million shsCOCPCocrystal Pharma$1.07$1.38$1.02▼$3.26$10.99M2.25303,719 shs105,747 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals0.00%-9.09%+56.68%-24.44%-83.41%ADTXAditxt0.00%-45.76%-67.71%-71.89%-99.88%ATNF180 Life Sciences+0.60%-15.15%-26.64%-10.64%-74.03%COCPCocrystal Pharma0.00%-6.96%-15.75%-34.76%-51.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.00355.88% UpsideADTXAditxt 1.00SellN/AN/AATNF180 Life Sciences 1.00SellN/AN/ACOCPCocrystal Pharma 2.00Hold$6.00460.75% UpsideCurrent Analyst Ratings BreakdownLatest ADTX, ATNF, ACXP, and COCP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ACXPAcurx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ADTXAditxtWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025COCPCocrystal PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$31.009/27/2025ACXPAcurx PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ADTXAditxtWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell ➝ Sell (E+)9/27/2025COCPCocrystal PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/14/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/12/2025ACXPAcurx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.007/29/2025ATNF180 Life SciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 10/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$0.63 per shareN/AADTXAditxt$130K12.49N/AN/A($1.52) per share-0.21ATNF180 Life SciencesN/AN/AN/AN/A$2.91 per shareN/ACOCPCocrystal PharmaN/AN/AN/AN/A$0.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$14.10M-$10.69N/AN/AN/AN/A-436.83%-192.25%11/11/2025 (Estimated)ADTXAditxt-$34.45MN/A0.00∞N/A-206,431.38%-316.98%-80.88%11/17/2025 (Estimated)ATNF180 Life Sciences-$6.17M-$15.07N/A∞N/AN/A-141.25%-80.77%11/12/2025 (Estimated)COCPCocrystal Pharma-$17.50M-$1.24N/AN/AN/AN/A-144.12%-102.85%11/12/2025 (Estimated)Latest ADTX, ATNF, ACXP, and COCP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025N/ACOCPCocrystal Pharma-$0.21N/AN/AN/AN/AN/A11/11/2025Q3 2025ACXPAcurx Pharmaceuticals-$1.61N/AN/AN/AN/AN/A8/14/2025Q2 2025ADTXAditxtN/A-$3.45N/A-$3.45N/AN/A8/14/2025Q2 2025COCPCocrystal Pharma-$0.30-$0.20+$0.10-$0.20N/AN/A8/11/2025Q2 2025ACXPAcurx Pharmaceuticals-$2.00-$1.89+$0.11-$1.89N/AN/A7/23/2025Q2 2025ATNF180 Life SciencesN/A-$0.30N/A-$0.30N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/AADTXAditxtN/AN/AN/AN/AN/AATNF180 Life SciencesN/AN/AN/AN/AN/ACOCPCocrystal PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A2.382.38ADTXAditxtN/A0.020.02ATNF180 Life SciencesN/A0.580.58COCPCocrystal PharmaN/A3.693.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%ADTXAditxt15.54%ATNF180 Life Sciences4.07%COCPCocrystal Pharma6.72%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%ADTXAditxt0.01%ATNF180 Life Sciences38.20%COCPCocrystal Pharma28.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals31.58 million1.26 millionOptionableADTXAditxt604.98 million4.98 millionNo DataATNF180 Life Sciences76.04 million3.73 millionNo DataCOCPCocrystal Pharma1010.27 million7.38 millionNot OptionableADTX, ATNF, ACXP, and COCP HeadlinesRecent News About These CompaniesCocrystal Pharma (NASDAQ:COCP) Trading Down 0.8% - What's Next?October 8, 2025 | americanbankingnews.comCocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity ConferenceOctober 2, 2025 | globenewswire.comCocrystal Pharma files to sell 5.74M shares of common stock for holdersSeptember 19, 2025 | msn.comAnother Norovirus Biotech Skyrockets: Hype or Hope?September 18, 2025 | acsh.orgACocrystal Pharma, Inc. Closes $4.7 Million Registered Direct Offering with Additional $8.3 Million Potential from WarrantsSeptember 15, 2025 | quiverquant.comQCocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSeptember 15, 2025 | globenewswire.comCocrystal Pharma announces up to $13M registered direct offeringSeptember 12, 2025 | msn.comCocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSeptember 12, 2025 | globenewswire.comCocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus ConferenceSeptember 12, 2025 | globenewswire.comCocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and TreatmentSeptember 8, 2025 | globenewswire.comCocrystal Pharma to Participate at the H.C. Wainwright Global Investment ConferenceSeptember 3, 2025 | globenewswire.comCOCP: Norovirus Challenge Study to Initiate in 4Q25…August 19, 2025 | msn.comCocrystal Pharma reports Q2 EPS (20c), consensus (30c)August 14, 2025 | msn.comCocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development ProgramsAugust 14, 2025 | globenewswire.comCocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical ConferenceAugust 5, 2025 | globenewswire.comCocrystal Pharma to Present Data from Phase 1 Study of First-in-Class ...July 11, 2025 | finance.yahoo.comCocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus ConferenceJuly 10, 2025 | globenewswire.comCocrystal Pharma Holds 2025 Annual Stockholders MeetingJuly 3, 2025 | theglobeandmail.comCocrystal PharmaJune 24, 2025 | geekwire.comGH.C. Wainwright lowers Cocrystal Pharma stock price target on dilutionJune 21, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADTX, ATNF, ACXP, and COCP Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$6.80 -0.23 (-3.27%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$6.82 +0.02 (+0.24%) As of 10/17/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.Aditxt NASDAQ:ADTX$0.33 -0.10 (-22.65%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.32 0.00 (-0.64%) As of 10/17/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.180 Life Sciences NASDAQ:ATNF$1.68 +0.01 (+0.60%) As of 10/17/2025180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.Cocrystal Pharma NASDAQ:COCP$1.07 0.00 (0.00%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$1.06 -0.02 (-1.40%) As of 10/17/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
